Home  
  Our Team  
  Services  
  VACCINATIONS  
  Contact Us  
Michael W. Shultz, DO
Michael W. Shultz, DO
Biography

News for Healthier Living

Cablivi Approved for Rare Clotting Disorder

WEDNESDAY, Feb. 6, 2019 (HealthDay News) -- Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and deadly disorder that causes blood clotting.

"Patients with aTTP endure hours of treatment with daily plasma exchange, which requires being attached to a machine that takes blood out of the body and mixes it with donated plasma and then returns it to the body. Even after days or weeks of this treatment, as well as taking drugs that suppress the immune system, many patients will have a recurrence of aTTP," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence.

People with aTTP develop blood clots in the small blood vessels throughout the body. The clots can cut off oxygen and blood supply to the major organs and cause strokes and heart attacks, the agency said Wednesday in a news release. Patients with cancer, HIV, pregnancy, lupus or infections are at greater risk of developing the disorder.

Cablivi was evaluated in clinical studies involving 145 people. Those treated with Cablivi had fewer instances of aTTP-related death, the FDA said.

Common side effects include headache and bleeding of the nose or gums.

Cablivi's prescribing information includes a warning about the risk of severe bleeding. Health care providers should monitor closely people who also take blood-thinning medications, the FDA said.

The drug is produced by Ablynx, based in Belgium.

February 6, 2019
Copyright © 2019 HealthDay. All rights reserved.


April 21 2019

April 20 2019

April 19 2019

April 18 2019

April 17 2019

April 16 2019

April 15 2019

April 14 2019

April 13 2019

April 12 2019

April 11 2019

April 10 2019

April 9 2019

April 8 2019

Patient Portal Access


Copyright HealthBanks, Inc. All rights reserved. | Terms of Use | Privacy Policy